Jeroen Eikenboom
Overview
Explore the profile of Jeroen Eikenboom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Houben N, Fustolo-Gunnink S, Caram-Deelder C, Visser R, Bosma M, Fijnvandraat K, et al.
Vox Sang
. 2024 Nov;
120(1):55-62.
PMID: 39557418
Background And Objectives: Routine coagulation screens at birth are still standard in some European neonatal intensive care units (NICUs), although interpretation of these results is complex in preterm infants. It...
2.
Luijten D, Abbel D, Cannegieter S, Eikenboom J, den Exter P, Gussekloo J, et al.
J Thromb Haemost
. 2024 Oct;
23(2):588-599.
PMID: 39454882
Background: Managing older patients with acute pulmonary embolism (PE) is challenging due to their underrepresentation in clinical trials, comorbidities, and increased complication risk. Objectives: To evaluate risk assessment and management...
3.
van Kwawegen C, Fijnvandraat K, Kruip M, de Meris J, Schols S, Meijer K, et al.
Haemophilia
. 2024 Oct;
30(6):1348-1356.
PMID: 39403864
Introduction: The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most...
4.
van Kwawegen C, Atiq F, Endenburg D, Fijnvandraat K, van Galen K, Cnossen M, et al.
J Thromb Haemost
. 2024 Sep;
22(12):3460-3472.
PMID: 39343102
Background: Type 2B von Willebrand disease (VWD) is a bleeding disorder caused by gain-of-function variants in the VWF gene. The laboratory and clinical phenotype of type 2B VWD is heterogeneous....
5.
Punt M, van Leusden F, Bloemenkamp K, Coppens M, Driessens M, Heubel-Moenen F, et al.
Res Pract Thromb Haemost
. 2024 Aug;
8(5):102508.
PMID: 39165610
Background: Between 2002 and 2011, the incidence of severe primary postpartum hemorrhage (PPH) in Dutch women with von Willebrand disease (VWD) and hemophilia carriers (HCs) was 8% vs 4.5% in...
6.
de Jong C, van Dam L, Dronkers C, Eikenboom J, den Exter P, Ter Haar S, et al.
TH Open
. 2024 Jul;
8(3):e266-e272.
PMID: 38988975
The noninvasive magnetic resonance direct thrombus imaging (MRDTI) technique can be used to diagnose acute deep vein thrombosis (DVT), without the use of intravenous contrast. MRDTI holds the potential to...
7.
Goedhart T, Bukkems L, Zwagemaker A, Coppens M, Fijnvandraat K, Schols S, et al.
Res Pract Thromb Haemost
. 2024 May;
8(3):102397.
PMID: 38689619
Background: Pharmacokinetic (PK)-guided dosing is used to individualize factor (F)VIII and FIX replacement therapy. Objectives: This study investigates the reliability and feasibility of PK-guided prophylactic dosing of factor concentrates in...
8.
Laan S, de Boer S, Dirven R, van Moort I, Kuipers T, Mei H, et al.
J Thromb Haemost
. 2024 Apr;
22(7):2027-2038.
PMID: 38574861
Background: Endothelial colony-forming cells (ECFCs) derived from patients can be used to investigate pathogenic mechanisms of vascular diseases like von Willebrand disease. Considerable phenotypic heterogeneity has been observed between ECFC...
9.
de Boer S, Laan S, Dirven R, Eikenboom J
PLoS One
. 2024 Feb;
19(2):e0297465.
PMID: 38394102
Background: Endothelial cells generated from induced pluripotent stem cells (hiPSC-ECs) show the majority of endothelial cell characteristics and markers, such as cobblestone morphology and the expression of VEGF and VE-cadherin....
10.
Romano L, Schutte L, Van Hest R, Meijer K, Laros-van Gorkom B, Nieuwenhuizen L, et al.
Haemophilia
. 2024 Feb;
30(2):355-366.
PMID: 38343113
Introduction: Non-severe haemophilia A patient can be treated with desmopressin or factor VIII (FVIII) concentrate. Combining both may reduce factor consumption, but its feasibility and safety has never been investigated....